Derivation of ligands for the complement C3a receptor from the C-terminus of C5a

European Journal of Pharmacology

Volumn 745, Issue , 2014, Pages 176-181

  Halai, Reena ^a   Bellows Peterson, Meghan L ^b   Branchett, Will ^c   Smadbeck, James ^b   Kieslich, Chris A ^b,d   Croker, Daniel E ^a   Cooper, Matthew A ^a   Morikis, Dimitrios ^d   Woodruff, Trent M ^a   Floudas, Christodoulos A ^b   Monk, Peter N ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Princeton University   (United States)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d University of California Riverside   (United States)

Author keywords

C3a receptor; C5a1 receptor; Computational optimization; In silico sequence selection; Label free screening; Peptide design

Indexed keywords

ACPHE(ORNITHINE-PRO-CYCLOHEXYLAMINE-TRP-ARG); ARGININE; BENZHYDRYL DERIVATIVE; C5AR1 PROTEIN, HUMAN; COMPLEMENT C3A RECEPTOR; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT RECEPTOR; CYCLOPEPTIDE; LIGAND; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; SB 290157;

AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DEGRANULATION; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; MACROPHAGE; METABOLISM; PROTEIN ENGINEERING; RAT;

ANIMALS; ARGININE; BENZHYDRYL COMPOUNDS; CELL DEGRANULATION; CELL LINE; COMPLEMENT C5A; HUMANS; LIGANDS; MACROPHAGES; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PROTEIN ENGINEERING; RATS; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; RECOMBINANT PROTEINS;

EID: 84949116647     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.10.041     Document Type: Article

References (32)

1. R.S. Ames, P. Nuthulaganti, and C. Kumar In Xenopus oocytes the human C3a and C5a receptors elicit a promiscuous response to the anaphylatoxins FEBS Lett. 395 1996 157 159
2. W. Bautsch, T. Kretzschmar, T. Stuhmer, A. Kola, M. Emde, J. Kohl, A. Klos, and D. Bitter-Suermann A recombinant hybrid anaphylatoxin with dual C3a/C5a activity Biochem. J. 288 Pt 1 1992 261 266
3. M.L. Bellows-Peterson, H.K. Fung, C.A. Floudas, C.A. Kieslich, L. Zhang, D. Morikis, K.J. Wareham, P.N. Monk, O.A. Hawksworth, and T.M. Woodruff De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation J. Med. Chem. 55 2012 4159 4168
4. M.L. Bellows, H.K. Fung, M.S. Taylor, C.A. Floudas, A. Lopez de Victoria, and D. Morikis New compstatin variants through two de novo protein design frameworks Biophys. J. 98 2010 2337 2346
5. M.L. Bellows, M.S. Taylor, P.A. Cole, L. Shen, R.F. Siliciano, H.K. Fung, and C.A. Floudas Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework Biophys. J. 99 2010 3445 3453
6. S.A. Cain, and P.N. Monk The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg74 J. Biol. Chem. 277 2002 7165 7169
7. D.E. Croker, R. Halai, D.P. Fairlie, and M.A. Cooper C5a, but not C5a-des Arg, induces upregulation of heteromer formation between complement C5a receptors C5aR and C5L2 Immunol. Cell Biol. 91 2013 625 633
8. G. Drapeau, S. Brochu, D. Godin, L. Levesque, F. Rioux, and F. Marceau Synthetic C5a receptor agonists: pharmacology, metabolism and in vivo cardiovascular and hematologic effects Biochem. Pharmacol. 45 1993 1289 1299
9. J.A. Ember, N.L. Johansen, and T.E. Hugli Designing synthetic superagonists of C3a anaphylatoxin Biochemistry 30 1991 3603 3612
10. A.M. Finch, S.M. Vogen, S.A. Sherman, L. Kirnarsky, S.M. Taylor, and S.D. Sanderson Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity J. Med. Chem. 40 1997 877 884
11. A.M. Finch, A.K. Wong, N.J. Paczkowski, S.K.e. Wadi, D.J. Craik, D.P. Fairlie, and S.M. Taylor Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a J. Med. Chem. 42 1999 1965 1974
12. H.K. Fung, C.A. Floudas, M.S. Taylor, L. Zhang, and D. Morikis Toward full-sequence de novo protein design with flexible templates for human beta-defensin-2 Biophys. J. 94 2008 584 599
13. H.K. Fung, S. Rao, C.A. Floudas, O. Prokopyev, P.M. Pardalos, and F. Rendl Computational comparison studies of quadratic assignment like formulations for the in silico sequence selection problem in de novo protein design J. Comb. Optim. 10 2005 41 60
14. H.K. Fung, M.S. Taylor, and C.A. Floudas Novel formulations for the sequence selection problem in de novo protein design with flexible templates Optim. Method Softw. 22 2007 51 71
15. R. Halai, and M.A. Cooper Using label-free screening technology to improve efficiency in drug discovery Expert Opin. Drug Discov. 7 2012 123 131
16. R. Kawatsu, S.D. Sanderson, I. Blanco, N. Kendall, A.M. Finch, S.M. Taylor, and D. Colcher Conformationally biased analogs of human C5a mediate changes in vascular permeability J. Pharmacol. Exp. Ther. 278 1996 432 440
17. J.L. Klepeis, C.A. Floudas, D. Morikis, C.G. Tsokos, E. Argyropoulos, L. Spruce, and J.D. Lambris Integrated structural, computational and experimental approach for lead optimization: design of compstatin variants with improved activity J. Am. Chem. Soc. 125 2003 8422 8423
18. J.L. Klepeis, C.A. Floudas, D. Morikis, C.G. Tsokos, and J.D. Lambris Design of peptide analogs with improved activity using a novel de novo protein design approach Ind. Eng. Chem. Res. 43 2004 3817 3826
19. A. Klos, E. Wende, K.J. Wareham, and P.N. Monk International Union of Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors Pharmacol. Rev. 65 2013 500 543
20. R. Li, L.G. Coulthard, M.C. Wu, S.M. Taylor, and T.M. Woodruff C5L2: a controversial receptor of complement anaphylatoxin, C5a FASEB J. 27 2013 855 864
21. H.D. Manthey, T.M. Woodruff, S.M. Taylor, and P.N. Monk Complement component 5a (C5a) Int. J. Biochem. Cell Biol. 41 2009 2114 2117
22. M.M. Markiewski, and J.D. Lambris The role of complement in inflammatory diseases from behind the scenes into the spotlight Am. J. Pathol. 171 2007 715 727
23. P.N. Monk, J.E. Pease, and M.D. Barker C5a stimulus-secretion coupling in rat basophilic leukaemia (RBL-2H3) cells transfected with the human C5a receptor is mediated by pertussis and cholera toxin-sensitive G proteins Biochem. Mol. Biol. Int. 32 1994 13 20
24. P.N. Monk, A.M. Scola, P. Madala, and D.P. Fairlie Function, structure and therapeutic potential of complement C5a receptors Br. J. Pharmacol. 152 2007 429 448
25. Q. Peng, K. Li, S.H. Sacks, and W. Zhou The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses Inflamm. Allergy Drug Targets 8 2009 236 246
26. R. Rajgaria, S.R. McAllister, and C.A. Floudas Distance dependent centroid to centroid force fields using high resolution decoys Proteins 70 2008 950 970
27. R.C. Reid, M.K. Yau, R. Singh, J.K. Hamidon, A.N. Reed, P. Chu, J.Y. Suen, M.J. Stoermer, J.S. Blakeney, J. Lim, J.M. Faber, and D.P. Fairlie Downsizing a human inflammatory protein to a small molecule with equal potency and functionality Nat. Commun. 4 2013 2802
28. E.S. Reis, H. Chen, G. Sfyroera, P.N. Monk, J. Kohl, D. Ricklin, and J.D. Lambris C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay J. Immunol. 189 2012 4797 4805
29. Z.V. Schofield, T.M. Woodruff, R. Halai, M.C. Wu, and M.A. Cooper Neutrophils - a key component of ischemia-reperfusion injury Shock 40 2013 463 470
30. C.C.G. Scully, J.S. Blakeney, R. Singh, H.N. Hoang, G. Abbenante, R.C. Reid, and D.P. Fairlie Selective hexapeptide agonists and antagonists for human complement C3a receptor J. Med. Chem. 53 2010 4938 4948
31. Taylor S.M. and Fairlie D.P., Discovery of potent cyclic antagonists of human C5a receptors. in: Morikis I. and Lambris J., Structural Biology of the Complement System 2005 CRC Press, Taylor and Francis New York, pp 341-362.
32. M.C. Wu, F.H. Brennan, J.P. Lynch, S. Mantovani, S. Phipps, R.A. Wetsel, M.J. Ruitenberg, S.M. Taylor, and T.M. Woodruff The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization Proc. Natl. Acad. Sci. USA 110 2013 9439 9444